Latest News

Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi® Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.

Tokyo, Japan — October 2026 — Global Regulatory Partners Japan (GRP Japan) is pleased to announce that it has joined the Japan Radiopharmaceuticals Association, effective October 2026. The membership marks an important step in GRP Japan’s continued expansion into the radiopharmaceutical and nuclear medicine sector, complementing the company’s established capabilities in pharmaceuticals, biologics, medical devices, and diagnostics. As a Marketing Authorization Holder (MAH) and local regulatory partner for international healthcare companies entering Japan, GRP Japan is expanding its capabilities to support the specialized regulatory, quality, importation, supply-chain, and lifecycle requirements associated with radiopharmaceutical products. Through its membership, GRP Japan looks forward to industry collaboration and to contributing its regulatory and market-access experience to the continued development of the sector in Japan.

Global Regulatory Partners (GRP) is pleased to announce its participation in BioJapan  2026, where GRP will exhibit at Booth C-41 and participate in the event's international Partnering program. BioJapan  2026 is observing its 40th anniversary as the world’s longest running biotechnology event.  It is held together with concurrent events,Regenerative Medicine JAPAN, and healthTECH JAPAN, bringing together biotechnology, pharmaceuticals, regenerative medicine, digital health, academia, investors, service providers, and other life-science stakeholders from Japan and around the world.

Tokyo, Japan – August 25, 2026 – Global Regulatory Partners GK (GRP GK) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on August 24, 2026, for Pegfilgrastim BS Subcutaneous Injection 3.6 mg 「GRP」, a pegfilgrastim biosimilar indicated for the prevention of febrile neutropenia associated with cancer chemotherapy.